行情

IOVA

IOVA

Iovance
NASDAQ

实时行情|Nasdaq Last Sale

22.25
-0.45
-1.98%
盘后: 22.25 0 0.00% 16:41 01/24 EST
开盘
22.70
昨收
22.70
最高
22.77
最低
21.78
成交量
121.55万
成交额
--
52周最高
29.68
52周最低
8.31
市值
28.08亿
市盈率(TTM)
-16.4061
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

IOVA 新闻

  • 去年全球贸易额或出现10年来首次下滑
  • 新浪财经.15分钟前
  • 意大利民粹主义阵营关键地方选举落败 提振执政联盟
  • 新浪财经综合.23分钟前
  • 打造干净市容!曼谷计划2021年电缆全面地下化
  • 中国新闻网.39分钟前
  • 降息+QE还不够 美联储考虑让二战抗衰退工具重出江湖
  • 新浪财经综合.55分钟前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

IOVA 简况

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
展开

Webull提供Iovance Biotherapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。